Influence of a COVID-19 vaccine's effectiveness and safety profile on vaccination acceptance.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
09 03 2021
Historique:
entrez: 23 2 2021
pubmed: 24 2 2021
medline: 5 3 2021
Statut: ppublish

Résumé

Although a safe and effective vaccine holds the greatest promise for resolving the COVID-19 pandemic, hesitancy to accept vaccines remains common. To explore vaccine acceptance decisions, we conducted a national survey of 1,000 people from all US states in August of 2020 and a replication in December of 2020. Using a 3 × 3 × 3 factorial experimental design, we estimated the impact of three factors: probability of 1) protection against COVID-19, 2) minor side effects, and 3) a serious adverse reactions. The outcome was respondents' reported likelihood of receiving a vaccine for the coronavirus. Probability of vaccine efficacy (50%, 70%, or 90%) had the largest effect among the three factors. The probability of minor side effects (50%, 75%, 90%) including fever and sore arm, did not significantly influence likelihood of receiving the vaccine. The chances of a serious adverse reaction, such as temporary or permanent paralysis, had a small but significant effect. A serious adverse reaction rate of 1/100,000 was more likely to discourage vaccine use in comparison to rates of 1/million or 1/100 million. All interactions between the factors were nonsignificant. A replication following the announcement that vaccines were 95% effective showed small, but significant increases in the likelihood of taking a vaccine. The main effects and interactions in the model remained unchanged. Expected benefit was more influential in respondents' decision making than expected side effects. The absence of interaction effects suggests that respondents consider the side effects and benefits independently.

Identifiants

pubmed: 33619178
pii: 2021726118
doi: 10.1073/pnas.2021726118
pmc: PMC7958192
pii:
doi:

Substances chimiques

COVID-19 Vaccines 0

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Déclaration de conflit d'intérêts

The authors declare no competing interest.

Références

MMWR Morb Mortal Wkly Rep. 2019 Feb 15;68(6):135-139
pubmed: 30763298
Lancet Infect Dis. 2016 Aug;16(8):942-51
pubmed: 27061888
Urology. 2017 Jan;99:246-253
pubmed: 27645527
EClinicalMedicine. 2020 Sep;26:100495
pubmed: 32838242
BMJ Glob Health. 2020 Oct;5(10):
pubmed: 33097547
Clin Cardiol. 2018 Jun;41(6):855-861
pubmed: 29696664
JAMA Netw Open. 2020 Oct 1;3(10):e2025594
pubmed: 33079199
Hum Vaccin Immunother. 2013 Aug;9(8):1763-73
pubmed: 23584253
PLoS One. 2017 Jan 26;12(1):e0170550
pubmed: 28125629
Paediatr Drugs. 2020 Apr;22(2):105-111
pubmed: 32072472
MMWR Morb Mortal Wkly Rep. 2021 Jan 29;70(4):125-129
pubmed: 33507892
MMWR Recomm Rep. 2002 Apr 12;51(RR-3):1-31
pubmed: 12002171
Am J Public Health Nations Health. 1958 Feb;48(2):139-41
pubmed: 13521059

Auteurs

Robert M Kaplan (RM)

Clinical Excellence Research Center, Stanford University School of Medicine, Stanford, CA 94305 bob.kaplan@stanford.edu.

Arnold Milstein (A)

Clinical Excellence Research Center, Stanford University School of Medicine, Stanford, CA 94305.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH